PhKv a toxin isolated from the spider venom induces antinociception by inhibition of cholinesterase activating cholinergic system

• Published in: Scandinavian journal of pain Vol. 17; no. 1; pp. 203 - 210
• Main Authors: Rigo, Flavia Karine, Rossato, Mateus Fortes, Trevisan, Gabriela, De Prá, Samira Dal-Toé, Ineu, Rafael Porto, Duarte, Mariane Bernardo, de Castro Junior, Célio José, Ferreira, Juliano, Gomez, Marcus Vinicius
• Format: Journal Article
• Language: English
• Published: Germany Elsevier B.V 01.10.2017; De Gruyter
• Subjects: Acetylcholinesterase; Antinociception; Muscarinic receptors; Nicotinic receptors; Pain; PhKv; Antinociception; Pain; Muscarinic receptors; Nicotinic receptors; Acetylcholinesterase; PhKv
• ISSN: 1877-8860; 1877-8879
• DOI: 10.1016/j.sjpain.2017.09.019

•PhKv, a peptide from P. nigriventer spider venom, does not affect thermal or mechanical sensitivity in mice.•PhKv caused antinociception in the chronic constriction injury model and after intraplantar injection of capsaicin.•Pretreatment of mice with atropine or mecamylamine inhibited neostigmine and PhKv-induced antinociception.•The antinociceptive activity of PhKv may be mediated by inhibition of AChE.•The inhibition of AChE activity by PhkV is competitive. Cholinergic agents cause antinociception by mimicking the release of acetylcholine (ACh) from spinal cholinergic nerves. PhKv is a peptide isolated from the venom of the armed spider Phoneutria nigriventer. It has an antiarrythmogenic activity that involves the enhanced release of acetylcholine. The aim of this study was to investigate whether PhKv had an antinociceptive action in mice. Male albino Swiss mice (25–35g) were used in this study. The PhKv toxin was purified from a PhTx3 fraction of the Phoneutria nigriventer spider's venom. Because of its peptide nature, PhKv is not orally available and it was delivered directly into the central nervous system by an intrathecal (i.t.) route. PhKV on the thermal and mechanical sensitivity was evaluated using plantar test apparatus and the up-and-down method. The analgesic effects of PhKv were studied in neuropathic pain (CCI) and in the peripheral capsicin test. In order to test whether PhKv interfered with the cholinergic system, the mice were pre-treated with atropine (5mg/kg, i.p.) or mecamylamine (0.001mg/kg, i.p.) and the PhKv toxin (30pmol/site i.t.) or neostigmine (100pmol/site) were applied 15min before the intraplantar capsaicin (1nmol/paw) administrations. To investigate PhKv action on the AChE activities, was performed in vitro and ex vivo assay for AChE. For the in vitro experiments, mice spinal cord supernatants of tissue homogenates (1mg/ml) were used as source of AChE activity. The AChE assay was monitored at 37°C for 10min in a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices) at 405nm. PhKv (30 and 100pmol/site, i.t.) had no effect on the thermal or mechanical sensitivity thresholds. However, in a chronic constriction injury model of pain, PhKv (10pmol/site, i.t.) caused a robust reduction in mechanical withdrawal with an antinociceptive effect that lasted 4h. A pretreatment in mice with PhKv (30pmol/site, i.t.) or neostigmine (100pmol/site, i.t.) 15min before an intraplantar injection of capsaicin (1nmol/paw) caused a maximal antinociceptive effect of 69.5±4.9% and 85±2.5%, respectively. A pretreatment in mice with atropine; 5mg/kg, i.p. or mecamylamine 0.001mg/kg, i.p. inhibited a neostigimine and PhKv-induced antinociception, suggesting a cholinergic mechanism. Spinal acetylcholinesterase was inhibited by PhKv with ED50 of 7.6 (4.6–12.6pmol/site, i.t.). PhKv also inhibited the in vitro AChE activity of spinal cord homogenates with an EC50 of 20.8 (11.6–37.3nM), shifting the Km value from 0.06mM to 18.5mM, characterizing a competitive inhibition of AChE activity by PhKv. Our findings provide, to our knowledge, the first evidence that PhKv caused inhibition of AChE, it increased the ACh content at the neuronal synapses, leading to an activation of the cholinergic system and an antinociceptive response. Studies regarding the nociceptive mechanisms and the identification of potential targets for the treatment of pain have become top priorities. PhKv, by its action of stimulating the cholinergic receptors muscarinic and nicotinic system, reduces pain it may be an alternative for controlling the pain processes.